Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1...read more
November’s IPO market struggled to take off amid a US government shutdown at the start of the month and a slump in tech stocks. Even still, eleven new listings managed to raise a combined $2.3 billion, below the month’s historical 10-year average...read more
US IPO Week Ahead: Markets set for a quiet week after year’s first sizable IPO
...read more
US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1 ...read more
Renaissance Capital's November IPO Market Update
November’s IPO market struggled to take off amid a US government shutdown at the start of the month and a slump in tech stocks. Even still, eleven new listings managed to raise a combined $2.3 billion, below the month’s historical 10-year average...read more
US IPO Week Ahead: December to start on a quiet note, some notable deals may launch
No IPOs are currently scheduled to price in the week ahead. We expect the 2025 IPO calendar to start December on relatively quiet note, although a handful of issuers may still look to price before year end. Medical supplies giant Medline (MDLN) remains the...read more